Authors: Flanigan, RC DeLaurentis, DA Waters, WB Kunz, K

Citation: Rc. Flanigan et al., Bacillus Calmette-Guerin: Is monthly maintenance an option for transitional cell carcinoma of the bladder?, UROL ONCOL, 6(1), 2001, pp. 16-19

Authors: Mercader, M Bodner, BK Moser, MT Kwon, PS Park, ESY Manecke, RG Ellis, TM Wojcik, EM Yang, D Flanigan, RC Waters, WB Kast, WM Kwon, ED

Citation: M. Mercader et al., T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer, P NAS US, 98(25), 2001, pp. 14565-14570

Authors: Freeman, VL Meydani, M Yong, S Pyle, J Durazo-Arvizu, R Liao, YL Flanigan, RC Waters, WB

Citation: Vl. Freeman et al., Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?, AM J CLIN N, 73(4), 2001, pp. 815-820

Authors: Gao, X Mohideen, N Flanigan, RC Waters, WB Wojcik, EM Leman, CR

Citation: X. Gao et al., The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection, J UROL, 164(6), 2000, pp. 1982-1986

Authors: Freeman, VL Meydani, M Yong, S Pyle, J Flanigan, RC Waters, WB Wojcik, EM

Citation: Vl. Freeman et al., Prostatic levels of fatty acids and the histopathology of localized prostate cancer, J UROL, 164(6), 2000, pp. 2168-2172

Authors: Clark, JI Gaynor, ER Martone, B Budds, SC Manjunath, R Flanigan, RC Waters, WB Sosman, JA

Citation: Ji. Clark et al., Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma, CLIN CANC R, 5(9), 1999, pp. 2374-2380